Hypertension Overview

Principles

Definition

Hypertension is the academic concept and research domain dedicated to understanding the pathology, epidemiology, clinical implications, and therapeutic approaches related to chronically elevated systemic arterial pressure. This field is paramount in biomedical science and public health due to hypertension's role as a leading modifiable risk factor for cardiovascular and renal diseases.

Ontological type

Pathophysiology

Therapeutic Strategies

Risk Factors

Key developments

Key Figures

Experimental and Renal Foundations era

Soma Weiss[1] was associated with Harvard University[2] and University of Massachusetts Boston[3] during the Experimental and Renal Foundations era. His key contribution, as documented in The quantitative aspects and dynamics of the circulatory mechanism in arterial hypertension[4], was to quantify circulatory dynamics in arterial hypertension, establishing quantitative, dynamic, hemodynamic analysis that linked microvascular processes to systemic pressure changes. This work[4] helped establish a mechanistic bridge between laboratory physiology and clinical management in this era, reinforcing the importance of precision hemodynamic measurement. Soma Weiss[1] thereby exemplified the experimental approach that anchored hemodynamic and reversibility frameworks guiding early hypertension research.

RAAS and Vascular Consolidation era

Scott M. Grundy [1] worked at Rockefeller University [3] and the Massachusetts Institute of Technology [4] during this era. His key contribution in this era was synthesizing the NCEP ATP II guidelines in the paper 'Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)' [7], which linked lipid management to overall cardiovascular risk in hypertensive populations and informed risk stratification and therapy strategies. Eugene Braunwald [2] was affiliated with Harvard University [5] and The University of Texas Southwestern Medical Center [6] during this era. His notable contribution is the 1996 paper 'The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels' [8], which demonstrated that statin therapy reduces recurrent coronary events and highlighted lipid-lowering strategies as integral to vascular risk management in hypertension-focused care.

Guideline-Driven Clinical Integration era

Jackson T. Wright [1] is associated with the American College of Preventive Medicine [3] and the University of California, San Francisco [4] in the Guideline-Driven Clinical Integration era. His key contributions in this era, evidenced by the JNC 7 Report [7] and the 2014 Evidence-Based Guideline [8], helped establish standardized targets and risk-based treatment algorithms that guided hypertension management. William C. Cushman [2] is affiliated with Harvard University [5] and Stanford University [6] during this era. His contributions, reflected in the JNC 7 Report [7] and the 2014 Evidence-Based Guideline [8], helped translate trial findings into guideline-based care and support the adoption of risk-based targets across diverse health systems.